Suppr超能文献

支气管扩张症中的气道清除技术:来自美国支气管扩张症和非结核分枝杆菌研究注册中心的分析。

Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry.

机构信息

New York University School of Medicine, New York, NY.

Research, the COPD Foundation, Miami, FL; College of Public Health, University of Kentucky, Lexington, KY.

出版信息

Chest. 2020 Oct;158(4):1376-1384. doi: 10.1016/j.chest.2020.06.050. Epub 2020 Jul 3.

Abstract

BACKGROUND

In patients with bronchiectasis, airway clearance techniques (ACTs) are important management strategies.

RESEARCH QUESTION

What are the differences in patients with bronchiectasis and a productive cough who used ACTs and those who did not? What was the assessment of bronchiectasis exacerbation frequency and change in pulmonary function at 1-year follow up?

STUDY DESIGN AND METHODS

Adult patients with bronchiectasis and a productive cough in the United States Bronchiectasis and NTM Research Registry were included in the analyses. ACTs included the use of instrumental devices and manual techniques. Stratified analyses of demographic and clinical characteristics were performed by use of ACTs at baseline and follow up. The association between ACT use and clinical outcomes was assessed with the use of unadjusted and adjusted multinomial logistic regression models.

RESULTS

Of the overall study population (n = 905), 59% used ACTs at baseline. A greater proportion of patients who used ACTs at baseline and follow up continuously had Pseudomonas aeruginosa (47% vs 36%; P = .021) and experienced an exacerbation (81% vs 59%; P < .0001) or hospitalization for pulmonary illness (32% vs 22%; P = .001) in the prior two years, compared with those patients who did not use ACTs. Fifty-eight percent of patients who used ACTs at baseline did not use ACTs at 1-year follow up. There was no significant change in pulmonary function for those who used ACTs at follow up, compared with baseline. Patients who used ACTs at baseline and follow up had greater odds for experiencing exacerbations at follow up compared with those patients who did not use ACTs.

INTERPRETATION

In patients with bronchiectasis and a productive cough, ACTs are used more often if the patients have experienced a prior exacerbation, hospitalization for pulmonary illness, or had P aeruginosa. There is a significant reduction in the use of ACTs at 1-year follow up. The odds of the development of a bronchiectasis exacerbation are higher in those patients who use ACTs continuously, which suggests more frequent use in an ill bronchiectasis population.

摘要

背景

在患有支气管扩张症的患者中,气道清除技术(ACT)是重要的管理策略。

研究问题

使用 ACT 和未使用 ACT 的支气管扩张症伴咳痰患者有何不同?在 1 年随访时,支气管扩张症加重频率和肺功能变化的评估结果如何?

研究设计和方法

在美国支气管扩张症和非结核分枝杆菌研究注册中心纳入患有支气管扩张症和有痰的成年患者进行分析。ACT 包括使用仪器设备和手动技术。根据基线和随访时使用 ACT 的情况,对人口统计学和临床特征进行分层分析。使用未调整和调整后的多项逻辑回归模型评估 ACT 使用与临床结局之间的关联。

结果

在整个研究人群(n=905)中,59%的患者在基线时使用 ACT。与未使用 ACT 的患者相比,在基线和连续随访时使用 ACT 的患者,更多的患者有铜绿假单胞菌(47%比 36%;P=0.021),且在过去两年内经历过加重(81%比 59%;P<0.0001)或因肺部疾病住院(32%比 22%;P=0.001)。在基线时使用 ACT 的 58%的患者在 1 年随访时未使用 ACT。与基线相比,在随访时使用 ACT 的患者的肺功能没有显著变化。与未使用 ACT 的患者相比,在基线和随访时使用 ACT 的患者在随访时发生加重的可能性更大。

结论

在患有支气管扩张症和有痰的患者中,如果患者先前经历过加重、因肺部疾病住院或有铜绿假单胞菌,他们更常使用 ACT。在 1 年随访时,ACT 的使用显著减少。在持续使用 ACT 的患者中,支气管扩张症加重的几率更高,这表明在患有支气管扩张症的患者中,ACT 的使用更为频繁。

相似文献

2
Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis.
Cochrane Database Syst Rev. 2017 Sep 27;9(9):CD011699. doi: 10.1002/14651858.CD011699.pub2.
3
Airway clearance techniques for bronchiectasis.
Cochrane Database Syst Rev. 2013 May 31(5):CD008351. doi: 10.1002/14651858.CD008351.pub2.
4
Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients.
Am J Respir Crit Care Med. 2024 Jul 1;210(1):108-118. doi: 10.1164/rccm.202307-1165OC.
6
Treatment adherence and health outcomes in patients with bronchiectasis.
BMC Pulm Med. 2014 Jul 1;14:107. doi: 10.1186/1471-2466-14-107.
7
[Hemoptysis in adults with bronchiectasis: correlation with disease severity and exacerbation risk].
Zhonghua Jie He He Hu Xi Za Zhi. 2017 Jan 12;40(1):16-23. doi: 10.3760/cma.j.issn.1001-0939.2017.01.005.
8
The Prevalence and Significance of Staphylococcus aureus in Patients with Non-Cystic Fibrosis Bronchiectasis.
Ann Am Thorac Soc. 2018 Mar;15(3):365-370. doi: 10.1513/AnnalsATS.201706-426OC.
9
Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.
Chest. 2017 May;151(5):982-992. doi: 10.1016/j.chest.2016.10.055. Epub 2016 Nov 23.
10
Effect of airway clearance techniques in patients experiencing an acute exacerbation of bronchiectasis: a systematic review.
Physiother Theory Pract. 2020 Dec;36(12):1300-1315. doi: 10.1080/09593985.2019.1579286. Epub 2019 Feb 18.

引用本文的文献

1
Addressing treatable traits in bronchiectasis through non-pharmacological therapies: a narrative review.
J Thorac Dis. 2025 Jun 30;17(6):4302-4322. doi: 10.21037/jtd-2024-2106. Epub 2025 Jun 18.
2
3
Comprehensive Management Algorithm for Complex Pulmonary Disease in the Real-World Setting.
Ann Am Thorac Soc. 2025 May;22(5):651-659. doi: 10.1513/AnnalsATS.202408-904FR.
4
Patient-managed interventions for adults with bronchiectasis: evidence, challenges and prospects.
Eur Respir Rev. 2024 Oct 30;33(174). doi: 10.1183/16000617.0087-2024. Print 2024 Oct.
5
Anti-Inflammatory and Anti-Oxidant Properties of N-Acetylcysteine: A Fresh Perspective.
J Clin Med. 2024 Jul 15;13(14):4127. doi: 10.3390/jcm13144127.
6
Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
Eur Respir J. 2024 Jun 6;63(6). doi: 10.1183/13993003.01689-2023. Print 2024 Jun.
8
Basic, translational and clinical aspects of bronchiectasis in adults.
Eur Respir Rev. 2023 Jun 7;32(168). doi: 10.1183/16000617.0015-2023. Print 2023 Jun 30.
10
Pilot Evaluation of a Management Toolkit for Airway Clearance Therapy in Bronchiectasis (IMPACT BE).
ATS Sch. 2023 Jan 30;4(1):76-86. doi: 10.34197/ats-scholar.2022-0061IN. eCollection 2023 Mar.

本文引用的文献

1
Respiratory physiotherapy in the bronchiectasis guidelines: is there a loud voice we are yet to hear?
Eur Respir J. 2019 Sep 28;54(3). doi: 10.1183/13993003.01610-2019. Print 2019 Sep.
2
The microbiome in bronchiectasis.
Eur Respir Rev. 2019 Sep 4;28(153). doi: 10.1183/16000617.0048-2019. Print 2019 Sep 30.
5
Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis.
Respirology. 2019 Mar;24(3):227-237. doi: 10.1111/resp.13459. Epub 2019 Jan 16.
6
US Patient-Centered Research Priorities and Roadmap for Bronchiectasis.
Chest. 2018 Nov;154(5):1016-1023. doi: 10.1016/j.chest.2018.06.032. Epub 2018 Jul 5.
7
Self-management for bronchiectasis.
Cochrane Database Syst Rev. 2018 Feb 7;2(2):CD012528. doi: 10.1002/14651858.CD012528.pub2.
8
Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis.
Am J Respir Crit Care Med. 2018 Jun 1;197(11):1410-1420. doi: 10.1164/rccm.201711-2202OC.
9
Treating Cough Due to Non-CF and CF Bronchiectasis With Nonpharmacological Airway Clearance: CHEST Expert Panel Report.
Chest. 2018 Apr;153(4):986-993. doi: 10.1016/j.chest.2018.01.014. Epub 2018 Jan 31.
10
ELTGOL airway clearance in bronchiectasis: laying the bricks of evidence.
Eur Respir J. 2018 Jan 11;51(1). doi: 10.1183/13993003.02232-2017. Print 2018 Jan.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验